These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 26872982

  • 1. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
    Calò LA, Vertolli U, Pagnin E, Ravarotto V, Davis PA, Lupia M, Naso E, Maiolino G, Naso A.
    Life Sci; 2016 Mar 01; 148():80-5. PubMed ID: 26872982
    [Abstract] [Full Text] [Related]

  • 2. Increased rho-kinase activity in hypertensive patients with left ventricular hypertrophy.
    Gabrielli L, Winter JL, Godoy I, McNab P, Padilla I, Cordova S, Rigotti P, Novoa U, Mora I, García L, Ocaranza MP, Jalil JE.
    Am J Hypertens; 2014 Jun 01; 27(6):838-45. PubMed ID: 24363278
    [Abstract] [Full Text] [Related]

  • 3. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
    Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, Hafezi-Moghadam A, Ishibashi T.
    Diabetes; 2009 Jan 01; 58(1):215-26. PubMed ID: 18840783
    [Abstract] [Full Text] [Related]

  • 4. Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care.
    Ravera M, Noberasco G, Signori A, Re M, Filippi A, Cannavò R, Weiss U, Cricelli C, Deferrari G, Paoletti E.
    Am J Hypertens; 2013 May 01; 26(5):700-7. PubMed ID: 23391620
    [Abstract] [Full Text] [Related]

  • 5. Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling.
    Ocaranza MP, Fierro C, Jalil JE, Moya J, Gonzalez L, Molina C, Mancilla C.
    Clin Sci (Lond); 2018 Aug 31; 132(16):1837-1853. PubMed ID: 30065083
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of combined target-organ damage in patients with essential hypertension.
    Carpinella G, Pagano G, Buono F, Petitto M, Guarino G, Orefice G, Rengo G, Trimarco B, Morisco C.
    Am J Hypertens; 2015 Jan 31; 28(1):127-34. PubMed ID: 24936579
    [Abstract] [Full Text] [Related]

  • 7. Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients.
    Calò LA, Ravarotto V, Bertoldi G, Pagnin E, Rossi B, Rigato M, Davis PA, Proietti R.
    J Clin Med; 2020 Jan 07; 9(1):. PubMed ID: 31936157
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.
    Mera C, Godoy I, Ramírez R, Moya J, Ocaranza MP, Jalil JE.
    Ther Adv Cardiovasc Dis; 2016 Feb 07; 10(1):4-20. PubMed ID: 26490279
    [Abstract] [Full Text] [Related]

  • 9. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways.
    Wang N, Guan P, Zhang JP, Li YQ, Chang YZ, Shi ZH, Wang FY, Chu L.
    J Cell Biochem; 2011 Jul 07; 112(7):1920-9. PubMed ID: 21433064
    [Abstract] [Full Text] [Related]

  • 10. Rho-Kinase inhibitor fasudil suppresses high glucose-induced H9c2 cell apoptosis through activation of autophagy.
    Gao H, Hou F, Dong R, Wang Z, Zhao C, Tang W, Wu Y.
    Cardiovasc Ther; 2016 Oct 07; 34(5):352-9. PubMed ID: 27333569
    [Abstract] [Full Text] [Related]

  • 11. Left ventricular hypertrophy in chronic kidney disease: A diagnostic criteria comparison.
    Nardi E, Mulè G, Giammanco A, Mattina A, Geraci G, Nardi C, Averna M.
    Nutr Metab Cardiovasc Dis; 2021 Jan 04; 31(1):137-144. PubMed ID: 33092976
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study.
    Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T, Ohashi Y, Hishida A.
    Clin Exp Nephrol; 2019 Jan 04; 23(1):85-98. PubMed ID: 29951723
    [Abstract] [Full Text] [Related]

  • 13. Left ventricular hypertrophy in nondiabetic predialysis CKD.
    Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G.
    Am J Kidney Dis; 2005 Aug 04; 46(2):320-7. PubMed ID: 16112052
    [Abstract] [Full Text] [Related]

  • 14. Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: Interrelationship and impact on clinical outcomes.
    Kim Y, Cho JS, Cho WK, Yoon HE, Hong YA, Chang YK, Yang CW, Kim SY, Hwang HS.
    Int J Cardiol; 2017 Dec 15; 249():372-376. PubMed ID: 29121742
    [Abstract] [Full Text] [Related]

  • 15. Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
    Waddingham MT, Edgley AJ, Astolfo A, Inagaki T, Fujii Y, Du CK, Zhan DY, Tsuchimochi H, Yagi N, Kelly DJ, Shirai M, Pearson JT.
    Cardiovasc Diabetol; 2015 Jul 22; 14():92. PubMed ID: 26194354
    [Abstract] [Full Text] [Related]

  • 16. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
    Chen XY, Dun JN, Miao QF, Zhang YJ.
    Pharmacology; 2009 Jul 22; 83(2):67-79. PubMed ID: 19052484
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardioprotective effect of a combination of Rho-kinase inhibitor and p38 MAPK inhibitor on cardiovascular remodeling and oxidative stress in Dahl rats.
    Takeshima H, Kobayashi N, Koguchi W, Ishikawa M, Sugiyama F, Ishimitsu T.
    J Atheroscler Thromb; 2012 Jul 22; 19(4):326-36. PubMed ID: 22166971
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The association between socioeconomic disparities and left ventricular hypertrophy in chronic kidney disease: results from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kang E, Lee J, Kim HJ, Han M, Kim SW, Lee KB, Sung S, Yoo TH, Chung W, Ahn C, Oh KH.
    BMC Nephrol; 2018 Aug 16; 19(1):203. PubMed ID: 30115015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.